Pharmacists in Middle Island, New York


12 Pharmacists found in Middle Island
male pharmacist

Dr. Ali Zaidi, PARMD


Pharmacist
750 Middle Country Rd, Middle Island, NY 11953
631-924-0154    

female pharmacist

Mrs. Anne H Huang-kwok, RPH


Pharmacist
1235 Middle Country Rd, Middle Island, NY 11953
631-924-0684     631-345-3466

female pharmacist

Diane Lynn Gonzalez, PHARM. D


Pharmacist
750 Middle Country Rd, Middle Island, NY 11953
631-924-0154     631-924-0223



male pharmacist

Mr. Frank Sciortino, R.PH.


Pharmacist
750 Middle Country Rd, Middle Island, NY 11953
631-924-0154    

male pharmacist

Mr. Gilbert Feldman, PHARMACIST IN CHARGE


Pharmacist
864 Middle Country Rd, Rite Aid Pharmacy, Middle Island, NY 11953
631-924-8500     631-924-2041

male pharmacist

Mr. James Francis Stewart, RPH


Pharmacist
1235 Middle Country Rd, Middle Island, NY 11953
631-924-0684    

male pharmacist

Minsung Kim


Pharmacist
864 Middle Country Rd, Middle Island, NY 11953
631-924-8500    

female pharmacist

Myrlande Geiselman


Pharmacist
864 Middle Country Rd, Middle Island, NY 11953
631-924-8513    

female pharmacist

Rebecca Anne Walters, PHARM. D


Pharmacist
750 Middle Country Rd, Middle Island, NY 11953
631-924-0154    

male pharmacist

Mr. Stephen Vincent Miro, RPH


Pharmacist
750 Middle Country Rd, Middle Island, NY 11953
631-924-0154    

female pharmacist

Tammy Ng


Pharmacist
750 Middle Country Rd, Middle Island, NY 11953
631-924-0154    

female pharmacist

Ms. Theresa A Sowinski


Pharmacist
750 Middle Country Rd, Middle Island, NY 11953
631-924-0154    


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.